NexGen receives U.S. patent allowance for novel pathogenesis based seizure treatment

NexGen Biomedical, Inc.'s Founder has received a Notice of Allowance from the US Patent Office for a novel treatment method for seizures.

"The discovery of the common pathogenesis underlying seizures and migraines finally provides a coherent explanation for all of the observations and symptoms, a new understanding of the risk factors to be avoided, and most importantly allows for a novel pathogenesis based treatment approach in contrast to today's symptom based treatment approaches," according to NexGen's founder Mark Zamoyski.

There are roughly 50 million seizure patients and 300 million migraine sufferers worldwide.

"Seizure and migraine triggers mediate their actions via increased release of calcium ions from bone, which in turn alters nerve and muscle function.  Stabilizing the bone microenvironment to prevent the calcium ion spike can be accomplished by repurposing drugs used for treatment of osteoporosis or management of hypercalcemia,"  Mr. Zamoyski further noted.

Companies that already have such drugs include Eli Lilly, Amgen, Procter & Gamble, J&J, Upsher-Smith, Ferring, and Novartis. 

"NexGen will now seek an acquirer of the IP or a business partner who will finance the development of this new treatment for seizures and migraines," explained NexGen Business Advisor Richard Lepidi. 

SOURCE NexGen Biomedical, Inc.